Brii Biosciences Limited (BRIBF) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Beijing, 중국. 현재 CEO는 Zhi Hong.
BRIBF 을(를) 보유 IPO 날짜 2022-01-21, 98 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $135.65M.
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
